Director of the Center for the Development of Therapeutics, Broad Institute of MIT and Harvard
Alex Burgin is the Senior Director of the Center for the Development of Therapeutics (CDoT) at the Broad Institute of MIT and Harvard. CDoT is a professional drug discovery organization that works with Broad faculty and industry partners to advance novel drug discovery projects. Burgin has over 30 years’ experience spanning both industry and academia. Burgin completed his postdoctoral training at the National Institutes of Health and was Group Leader at Ribozyme Pharmaceuticals prior to joining the faculty of San Diego State University. He then joined Emerald BioStructures (now UCB Pharma) where, as COO and then as CSO, he led multiple drug discovery projects. Burgin served as the Senior Scientific Advisor to the Broad’s CSO and was named an Institute Scientist. Burgin was the Executive Director at the Institute for Protein Innovation before returning to the Broad. Burgin holds an A.B. from Wabash College and a Ph.D. from Indiana University.